TMPRSS2

Chr 21

transmembrane serine protease 2

Also known as: PRSS10

This gene encodes a protein that belongs to the serine protease family. The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain. Serine proteases are known to be involved in many physiological and pathological processes. This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue. The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage. This protein also facilitates entry of viruses into host cells by proteolytically cleaving and activating viral envelope glycoproteins. Viruses found to use this protein for cell entry include Influenza virus and the human coronaviruses HCoV-229E, MERS-CoV, SARS-CoV and SARS-CoV-2 (COVID-19 virus). Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2020]

ResearchGenerating clinical summary…
11
Active trials
365
Pubs (1 yr)
P/LP submissions
P/LP missense
0.94
LOEUF
Multiple*
Mechanism· predicted
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.94LOEUF
pLI 0.000
Z-score 1.81
OE 0.65 (0.460.94)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
0.40Z-score
OE missense 0.94 (0.851.03)
303 obs / 323.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.65 (0.460.94)
00.351.4
Missense OE?0.94 (0.851.03)
00.61.4
Synonymous OE?0.92
01.21.6
LoF obs/exp: 20 / 30.9Missense obs/exp: 303 / 323.2Syn Z: 0.76

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

TMPRSS2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Prostate Cancer

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

ACTIVE NOT RECRUITING
NCT02303327Phase PHASE3Sir Mortimer B. Davis - Jewish General HospitalStarted 2015-01
EBRT + HDR brachytherapy boostHypofractionated Dose Escalation RadiotherapyAndrogen deprivation therapy
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

RECRUITING
NCT03903835Phase PHASE3Karolinska InstitutetStarted 2019-02-01
Enzalutamide Oral CapsuleAbiraterone Oral TabletCarboplatin
Conditions Influencing Health StatusHealthyProstate Cancer

Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome

ACTIVE NOT RECRUITING
NCT01441687Phase NACity of Hope Medical CenterStarted 2009-07-14
laboratory biomarker analysistransrectal prostate biopsy
Post-Acute COVID-19 Syndrome

A Study of Apabetalone in Subjects With Long -COVID

RECRUITING
NCT06590324Phase PHASE2, PHASE3Resverlogix CorpStarted 2025-04-15
Apabetalone
Prostate CancerMetastatic Castration-resistant Prostate Cancer

ProsTIC Registry of Men Treated With PSMA Theranostics

ACTIVE NOT RECRUITING
NCT04769817Peter MacCallum Cancer Centre, AustraliaStarted 2021-05-19
177Lu-PSMA
Prostate Cancer

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

RECRUITING
NCT02573636Sir Mortimer B. Davis - Jewish General HospitalStarted 2016-03
Prostatic NeoplasmsLow Grade Prostate Cancer

Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression

ACTIVE NOT RECRUITING
NCT01653925Phase NACHU de Quebec-Universite LavalStarted 2010-10-28
Dietary intervention firstDrug (Dutasteride) intervention first
Metastatic Hormone Naive Prostate Cancer

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

ACTIVE NOT RECRUITING
NCT04343885Phase PHASE2Peter MacCallum Cancer Centre, AustraliaStarted 2020-04-21
177Lu-PSMA-617Docetaxel
PSAProstate Cancer

EDRN Prostate MRI Biomarker Study

RECRUITING
NCT03784924University of MichiganStarted 2019-02-04
MRI prostate
Prostate Cancer

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

RECRUITING
NCT01961713Massachusetts General HospitalStarted 2010-04
COVID-19Antibody COVID-19

The Role of Obesity in Severe COVID-19 Pathophysiology

RECRUITING
NCT06968442Phase NAFranciscus GasthuisStarted 2025-04-22
Venipuncture